0001144204-15-034844.txt : 20150601
0001144204-15-034844.hdr.sgml : 20150601
20150601162636
ACCESSION NUMBER: 0001144204-15-034844
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150528
FILED AS OF DATE: 20150601
DATE AS OF CHANGE: 20150601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CorMedix Inc.
CENTRAL INDEX KEY: 0001410098
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1430 HIGHWAY 206
STREET 2: SUITE 200
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: 908-517-9500
MAIL ADDRESS:
STREET 1: 1430 HIGHWAY 206
STREET 2: SUITE 200
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lefkowitz Steven W
CENTRAL INDEX KEY: 0001313149
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34673
FILM NUMBER: 15903712
MAIL ADDRESS:
STREET 1: SIX HARRISON STREET
CITY: NEW YORK
STATE: NY
ZIP: 10013
4
1
form474701_20150601042516-.xml
X0306
4
2015-05-28
0
0001410098
CorMedix Inc.
CRMD
0001313149
Lefkowitz Steven W
C/O CORMEDIX INC.
745 ROUTE 202-206, SUITE 303
BRIDGEWATER
NJ
US 08807
1
0
0
0
Common Stock, $0.001 par value per share
2015-05-28
4
S
0
10000
6.1602
D
146471
D
Common Stock, $0.001 par value per share
2015-06-01
4
S
0
29072
6.6558
D
117399
D
Common Stock, $0.001 par value per share
174741
I
Wade Capital Corporation Money Purchase Plan
Common Stock, $0.001 par value per share
10000
I
Reporting Person's Wife
Stock Option (right to buy)
2.02
2024-01-09
Common Stock, $0.001 par value per share
200000
200000
D
Stock Option (right to buy)
2.02
2024-01-09
Common Stock, $0.001 par value per share
30000
30000
D
Swries C-3 Non-Voting Convertible Preferred Stock
1
Common Stock, $0.001 par value per share
45000
4500
D
Warrant (right to purchase Common Stock)
0.9
2015-01-08
2020-01-08
Common Stock, $0.001 par value per share
22500
22500
D
Series C-3 Non-Voting Convertible Preferred Stock
1
Common Stock, $0.001 par value per share
30000
3000
I
Wade Capital Corporation Money Purchase Plan
Warrant (right to purchase Common Stock)
0.9
2015-01-08
2020-01-08
Common Stock, $0.001 par value per share
15000
15000
I
Wade Capital Corporation Money Purchase Plan
Warrant (right to purchase Common Stock)
3.4375
2012-08-20
2015-04-30
Common Stock, $0.001 par value per share
5000
0
D
Stock Option (right to buy)
0.9
2023-03-20
Common Stock, $0.001 par value per share
120000
120000
D
Stock Option (right to buy)
0.68
2022-12-05
Common Stock, $0.001 par value per share
150000
150000
D
Stock Option (right to buy)
0.29
2022-01-06
Common Stock, $0.001 par value per share
30000
30000
D
Stock Option (right to buy)
1.1
2021-08-11
Common Stock, $0.001 par value per share
30000
30000
D
Warrant (right to purchase Common Stock)
3.4375
2015-04-30
Common Stock, $0.001 par value per share
19536
0
D
Warrant (right to purchase Common Stock)
3.4375
2015-04-30
Common Stock, $0.001 par value per share
7900
0
D
Stock Option (right to buy)
5.62
2025-03-01
Common Stock, $0.001 par value per share
50000
50000
D
The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
The options vested 100% on January 10, 2014.
On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The warrant exercise price was decreased from $1.25 per share to $0.90 per share effective September 15, 2014. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
These options vest quarterly over two years beginning June 13, 2013.
These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
The options vest in full on the first anniversary of the date of grant.
The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of hte Company's registration statement related thereto.
The expiration date was originally 3/24/2015 and was extended to 4/30/2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices $6.15 to $6.17, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices $6.15 to $7.10, inclusive.
/s/Alexander M. Donaldson by Power of Attorney
2015-06-01